"24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

9026Background: Cohort G of the phase 1/2 KEYNOTE-021 study (NCT02039674) evaluated pembrolizumab (pembro) + pemetrexed and carboplatin (PC) vs PC in first-line advanced nonsquamous NSCLC. With med... Click to show full abstract

Keywords: first line; nonsquamous nsclc; cohort; pemetrexed carboplatin; keynote 021; advanced nonsquamous

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended